Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
335 GBX | +6.01% | +16.72% | +52.27% |
May. 03 | Jefferies cuts AJ Bell; Deutsche likes ConvaTec | AN |
Apr. 29 | FTSE 100 as investors look to Fed rate decision | AN |
Sales 2023 | 89.54M 112M | Sales 2024 * | 130M 162M | Capitalization | 335M 419M |
---|---|---|---|---|---|
Net income 2023 | -157M -196M | Net income 2024 * | -36M -44.98M | EV / Sales 2023 | 2.38 x |
Net cash position 2023 * | 49.23M 61.5M | Net cash position 2024 * | 14.93M 18.66M | EV / Sales 2024 * | 2.47 x |
P/E ratio 2023 |
-1.35
x | P/E ratio 2024 * |
-9.51
x | Employees | 714 |
Yield 2023 * |
-
| Yield 2024 * |
-
| Free-Float | 80.81% |
Latest transcript on Oxford Biomedica plc
1 day | +6.01% | ||
1 week | +16.72% | ||
Current month | +21.16% | ||
1 month | +66.67% | ||
3 months | +91.21% | ||
6 months | +57.28% | ||
Current year | +52.27% |
Managers | Title | Age | Since |
---|---|---|---|
Frank Mathias
CEO | Chief Executive Officer | 62 | 23-03-26 |
Stuart Paynter
DFI | Director of Finance/CFO | 52 | 17-08-28 |
Chairman | 68 | 20-06-23 |
Members of the board | Title | Age | Since |
---|---|---|---|
Leone Patterson
BRD | Director/Board Member | 61 | 23-04-30 |
Chairman | 68 | 20-06-23 | |
Stuart Henderson
BRD | Director/Board Member | 66 | 16-05-31 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.04% | 2 M€ | -.--% | ||
0.00% | 10 M€ | -3.35% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-05-08 | 335 | +6.01% | 428,729 |
24-05-07 | 316 | -3.66% | 1,013,899 |
24-05-03 | 328 | +9.33% | 1,141,114 |
24-05-02 | 300 | +4.53% | 325,249 |
24-05-01 | 287 | +3.80% | 495,431 |
Delayed Quote London S.E., May 08, 2024 at 11:35 am EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
+52.27% | 396M | |
+2.93% | 106B | |
+7.02% | 23.47B | |
-14.60% | 21.9B | |
-7.05% | 18.77B | |
-38.55% | 17.85B | |
-8.83% | 16.78B | |
+5.51% | 14.41B | |
+37.49% | 12.86B | |
+329.39% | 8.78B |
- Stock Market
- Equities
- OXB Stock